Close

Eyegate Pharma (EYEG) Achieves 75% Enrollment in Pivotal Phase 3 Trial for Anterior Uveitis Triggering Milestone Payment

December 18, 2017 8:34 AM EST Send to a Friend
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login